Online inquiry

IVTScrip™ mRNA-Anti-ITGAV&ITGB3, CNTO 095(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6002MR)

This product GTTS-WQ6002MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets ITGAV&ITGB3 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001144999.3; NM_000212.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3685; 3690
UniProt ID P06756; P05106
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ITGAV&ITGB3, CNTO 095(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ6002MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ236MR IVTScrip™ mRNA-Anti-B4GALNT1, 14.18 mAb(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA 14.18 mAb
GTTS-WQ6963MR IVTScrip™ mRNA-Anti-VEGFA, ESBA-1008(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ESBA-1008
GTTS-WQ2376MR IVTScrip™ mRNA-Anti-HGF, AMG 102(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AMG 102
GTTS-WQ1581MR IVTScrip™ mRNA-Anti-MSTN, ACE-083(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ACE-083
GTTS-WQ11627MR IVTScrip™ mRNA-Anti-LAG3&PDCD1, MGD-013(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MGD-013
GTTS-WQ14058MR IVTScrip™ mRNA-Anti-C5, REGN-3918(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA REGN-3918
GTTS-WQ349MR IVTScrip™ mRNA-Anti-ALB&IL6R, 20A11-9mer-ALB11(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA 20A11-9mer-ALB11
GTTS-WQ4778MR IVTScrip™ mRNA-Anti-TNFSF13B, BR3-Fc(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BR3-Fc
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW